tzahiV / iStockphoto.com
20 June 2017Big Pharma

General Court to hear drug competition cases following fines

The EU’s General Court will this month hear three competition cases involving generic companies, with the first—brought by Slovenian business Krka—being heard today.

The two other hearings, concerning Teva and Mylan Laboratories, will take place on Thursday, June 22 and Tuesday, June 27 respectively.

In 2014, the European Commission imposed fines which totalled €427.7 million ($477 million) on French pharmaceutical company Servier, as well five generic companies.

Besides the three companies mentioned, the two other drugs manufacturers also fined were Niche/Unichem and Matrix, which is now part of Mylan.

The companies were accused of taking part in several deals all aimed at protecting Servier’s perindopril drug, a blood pressure treatment, from EU competition.

According to a press release, Servier and the five generic companies have brought separate actions for the annulment of the Commission’s fines before the General Court.

Alternatively, the companies have asked the court to reduce the fines.

Today’s news:

Biopharma must target unpopularity, says Allergan

The success story of OmniRat

Intellia granted China patent for CRISPR technology

Fed Circuit invalidates diagnostics patents

Orexo sues Actavis and Teva

J&J reveals obesity and 3D printing collaborations

Merck granted its first CRISPR patent in Australia

Did you enjoy reading this story?  Sign up to our free newsletters and get stories like this sent straight to your inbox.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk